ANNOUNCEMENT

Save $300 on MedCity CONVERGE Healthcare Innovation Summit July 9-10 in Philadelphia. Earlybird rate ends May 20.

Topic: Targacept

Biopharma Targacept’s new CEO is Stephen Hill

Biopharma Targacept’s new CEO is Stephen Hill

November 15, 2012 8:56 am by | 0 Comments

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics , today announced that Stephen A. Hill, M.D. has been appointed as President and Chief Executive Officer. Dr. ... Read more
Targacept employees get bad news as company’s ADHD drug fails study

Targacept employees get bad news as company’s ADHD drug fails study

September 17, 2012 10:55 am by | 0 Comments

An experimental treatment for attention deficit hyperactivity disorder from Targacept Inc did not meet the main goal of a mid-stage trial, prompting the company to drop development of the drug ... Read more
Targacept CEO deBethizy resigns from the N.C. biotech

Targacept CEO deBethizy resigns from the N.C. biotech

June 4, 2012 12:17 pm by | 0 Comments

Targacept (NASDAQ:TRGT), already in the midst of a corporate restructuring, must now also search for a new CEO.Don deBethizy is resigning from his positions as CEO and chairman of the ... Read more
Targacept restructuring cuts drug discovery, refocuses on clinical work

Targacept restructuring cuts drug discovery, refocuses on clinical work

May 4, 2012 9:29 am by | 0 Comments

 Targacept’s (NASDAQ:TRGT) drug development effort is focused on the here, now and soon to be future.It has to be because a corporate restructuring that will lead to layoffs of 65 ... Read more
Targacept’s drug pipeline must fill gap left by lead drug’s phase 3 failure

Targacept’s drug pipeline must fill gap left by lead drug’s phase 3 failure

May 3, 2012 11:17 am by | 0 Comments

Targacept‘s (NASDAQ:TRGT) first quarter dealt the company several blows with a phase 3 clinical trial failure for its lead drug candidate and a missed target in another clinical program.Failure of ... Read more
Targacept restructuring plan calls for layoffs of 46 percent of workforce

Targacept restructuring plan calls for layoffs of 46 percent of workforce

April 25, 2012 3:12 pm by | 1 Comments

Targacept (NASDAQ:TRGT) is slashing its workforce by nearly half, part of a restructuring plan that comes one month after its lead drug candidate, a depression drug, failed the last of ... Read more
Asthma compound hits just one of two phase 2 goals, TRGT reanalysis shows

Asthma compound hits just one of two phase 2 goals, TRGT reanalysis shows

April 11, 2012 11:21 am by | 0 Comments

The asthma treatment Targacept (NASDAQ:TRGT) is developing actually did not perform as well in clinical trials as initially thought.Targacept last month released top-line phase 2 results for TC-6987 that showed ... Read more
Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials

Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials

March 27, 2012 10:47 am by | 0 Comments

A Targacept (NASDAQ:TRGT) compound developed for potential applications in asthma and type 2 diabetes has mixed mid-stage clinical trial results that show success in asthma but failure in diabetes.As a ... Read more
Targacept, AZN drop depression candidate after third phase 3 failure

Targacept, AZN drop depression candidate after third phase 3 failure

March 20, 2012 4:54 pm by | 0 Comments

Targacept (NASDAQ:TRGT) and AstraZeneca (NYSE:AZN) are dropping plans to seek regulatory approval on their depression drug candidate after the compound failed its remaining phase 3 clinical trials.The two drug companies ... Read more
Depression remains TRGT’s lead target, but CEO touts other shots on goal

Depression remains TRGT’s lead target, but CEO touts other shots on goal

February 21, 2012 6:59 pm by | 0 Comments

Depression treatment TC-5214 remains Targacept‘s (NASDAQ:TRGT) lead drug candidate and perhaps it was with that in mind that CEO Don DeBethizy started the earnings conference call with an update on ... Read more
AstraZeneca takes on TRGT’s Alzheimer’s disease drug candidate

AstraZeneca takes on TRGT’s Alzheimer’s disease drug candidate

January 5, 2012 1:07 pm by | 0 Comments

Targacept (NASDAQ:TRGT) has seen two phase 3 clinical trial failures in the last two months for its depression drug candidate. Now the company has some better news, albeit for a ... Read more
Why dosing matters in the phase 3 failure of Targacept’s depression drug

Why dosing matters in the phase 3 failure of Targacept’s depression drug

December 20, 2011 10:56 am by | 0 Comments

The depression treatment that Targacept (NASDAQ:TRGT) has identified as its lead drug candidate has failed in a phase 3 clinical trial, the second failure in less than two months for ... Read more
Targacept pins hopes on second set of phase 2 trials for schizophrenia, ADHD drug

Targacept pins hopes on second set of phase 2 trials for schizophrenia, ADHD drug

December 5, 2011 11:06 am by | 0 Comments

Drug development company Targacept (NASDAQ:TRGT) has started two mid-stage clinical trials on a compound that could have applications in schizophrenia as well as attention deficit-hyperactivity disorder.It’s the second round of ... Read more
TRGT, AZN depression drug’s future rides on three more phase 3 trials

TRGT, AZN depression drug’s future rides on three more phase 3 trials

November 8, 2011 12:07 pm by | 1 Comments

Targacept (NASDAQ:TRGT) remains committed to moving forward with three more phase 3 clinical trials attempting to develop depression’s first new treatment mechanism in decades despite results of one trial showing ... Read more
AstraZeneca, Targacept depression treatment fails in late-stage trial (Morning Read)

AstraZeneca, Targacept depression treatment fails in late-stage trial (Morning Read)

November 8, 2011 8:55 am by | 0 Comments

Current medical news from today, including promising AstraZeneca/Targacept depression drug fails in first Phase III trial, changes at Amag Pharmaceuticals, and a 3D endoscopy. ... Read more